ClinicalTrials.gg
TerminatedNCT00503516Updated Jun 8, 2011

Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients

A Phase 2/3 interventional study of Megestrol acetate and Placebo in Dementia, sponsored by Rottapharm Spain. Terminated at 1 site in Spain. Open to participants aged 65 Years to 95 Years. Per ClinicalTrials.gov, last updated 2011-06-08.

Sponsored by Rottapharm Spain · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Difficulties to recruit the patients following the inclusion criteria

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
65 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Dementia with a site in Spain — 27 open to participants now, 37 under way, 9 of them phase 3. Dementia · Spain.

Enrollment
83rd of 95
39 · median 240
Started
2007
with 2 others
Phase 2/3
11 of 114
3 open now
Registered
7th of 114
by date

Among the 114 studies in Dementia with a site in Spain, this one is the 83rd largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 2/3, and was the 7th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

27 of the 114 studies in Dementia with a site in Spain are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 65 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Dementia with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy of megestrol acetate in the gain of body weight in patients with primary or mixed Dementia with a weight loss.

Read the detailed description

In all geriatric patients with dementia it was prove a weight loss independently if they are institutionalized or not.There are some previous studies that indicates the effect of the megestrol acetate in the weight gain of patients with cachexia-anorexia related with neoplasia. It seems that the mechanism of development could be the same between these patients and patients with dementia. It was described an important role of a group of cytokines ( Il-6, leptin, neuropeptide Y, TNFalfa) in the development of this nutritional alteration.

Some previous pilots studies indicates that megestrol acetate has and effect in geriatric and dementia patients with a weight loss of at least 5% in the last 6 months.

03

Conditions studied

  • Dementia

Keywords

  • weight loss, appetite, dementia, megestrol acetate
04

Who can participate

Ages eligible
65 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed of primary or mixed dementia (CIE 10criteria)
  • Weihgt loss >5% of habitual weight in the last 6 months and proteic-caloric malnutrition (MNA \<17)
  • Outpatients
  • Patients that accept the participation in the study

Exclusion criteria

Exclusion Criteria:

  • Vascular pure Dementia and secondary dementias( vascular dementia, Parkinson disease,etc)
  • Dementia in a terminal phase: category of FAST 7c in the Reisber scale
  • Concomitant treatment with , androgens or other drugs with progestagens
  • Weight loss secondary to neoplasia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    1

    Megestrol acetate 160 mg b.i.d. during 24 weeks

    Drug: Megestrol acetate

  • Placebo comparator
    2

    1 sachet of powder of placebo b.i.d. during 24 weeks

    Drug: Placebo

Interventions

  • 1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks

  • DrugPlacebo

    1 sachet of 160 mg of placebo b.i.d.

06

What researchers measure

Primary outcomes

  1. To evaluate the change in the body weight

    Time frame: 24 weeks

Secondary outcomes

  1. To evaluate the change in the appetite

    Time frame: 24 weeks

  2. To evaluate the change in biochemical markers: Il-6, Il-1, leptin, TNFalfa, neuropeptide Y, albumin and prealbumin

    Time frame: 24 weeks

  3. Evaluate the change in the nutritional status (Mini-Nutritional Assessment)

    Time frame: 24 weeks

  4. To evaluate the change in cognitive state ( Mini-Mental State Examination)

    Time frame: 24 weeks

  5. To evaluate the safety of the treatment

    Time frame: 24 weeks

07

Study locations

1 site
  • Hospital Socio Sanitario del Hospitalet
    El Hospitalet, Barcelona 08906, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 18, 2007
Start
Jun 2007
Primary completionActual
Dec 2009
CompletionActual
Feb 2010
Last update
Jun 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00503516
Lead sponsor
Rottapharm Spain
First posted
Jul 18, 2007
Start date
Jun 2007
Primary completion
Dec 2009
Completion
Feb 2010
Last update
Jun 8, 2011

Study contacts

Pau Sánchez, MD
study chair · Hospital Socio Sanitario del Hospitalet (Barcelona)
Salvador Altimir, MD
principal investigator · Hospital Universitari Germans Trias i Pujol (Badalona)
Ramón Cristófol, MD
principal investigator · Antic Hospital Sant Jaume i Santa Magdalena (Mataró)
Olga Sabartés, MD
principal investigator · Hospital del Mar
Enrique Arriola, MD
principal investigator · Fundación Matia (San Sebastián)
José Luis González, MD
principal investigator · Hospital Nuestra Señora de la Montaña (Cáceres)
Esher Martínez, MD
principal investigator · Hospital de la Santa Creu (Tortosa)
Roberto Petidier, MD
principal investigator · Hospital Universitario de Getafe (Madrid)
Esperanza Martin, MD
principal investigator · Hospital Virgen del Valle (Toledo)
Almudena Garnica, MD
principal investigator · Hospital Universitari San Joan de Reus (Tarragona)
Regina Feijoo, MD
principal investigator · Hosp. Sta. Caterina Gerona
Anna Tantiña, MD
principal investigator · CAP Centelles (Barcelona)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion